Kyrgyzstan Medical Device Authorized Representative: Resident Entity and Liability Requirements

1. Key takeaways

Kyrgyzstan has a clear statutory definition of the authorized representative of a manufacturer, set out in Article 2 of Annex 1 to Cabinet Resolution No. 513: a legal entity registered in the Kyrgyz Republic, or a natural person registered as an individual entrepreneur, who is a resident of the Kyrgyz Republic, who is empowered by a power of attorney issued by the manufacturer, and who represents its interests and bears responsibility for the circulation of the devices and for compliance with the mandatory requirements imposed on them. Four elements, namely entity form, resident status, power of attorney authorization, and assumption of responsibility, must all be present at the same time. The four words bear responsibility are the core of this provision: the authorized representative is a liability node, not a mailing address.

2. Legal basis

1. Cabinet Resolution No. 513, August 27, 2024, Annex 1, Article 2: definition of the authorized representative of a manufacturer, a legal entity registered in the Kyrgyz Republic or a natural person registered as an individual entrepreneur who is a resident of the Kyrgyz Republic, empowered by the power of attorney of the manufacturer, representing its interests and bearing responsibility for the circulation of medical devices and for compliance with the mandatory requirements imposed on them.
2. Law No. 216, Article 14: the obligation to report changes to device data and information rests with the manufacturer or its authorized representative.
3. Law No. 216, Article 30: the holder of a foreign registration certificate, the authorized representative office of the manufacturer, or a commissioned agent may import devices for registration and expert review purposes.
4. Law No. 216, Article 15: registration certificates are issued for an unlimited period; providing false information and similar circumstances constitute grounds for revocation.
5. Annex 1 to Cabinet Resolution No. 513: the registration dossier must record the information of the authorized representative (the concepts of applicant and authorized representative are set out in Article 2).

3. Expert insights

Insight 1: the residency requirement completely closes off the remote self-service route.

The definition expressly requires the authorized representative to be a resident of the Kyrgyz Republic. This is not a formal threshold but a substantive local-presence requirement. It means that a foreign manufacturer cannot act as its own authorized representative, nor can an entity from a third country take on this role directly. Combined with the fact that the entire process must be handled in the IS EBD LS i MI electronic system (see Part 02 of this series), establishing a local entity in Kyrgyzstan is a necessary condition of market access, not an optional extra.

Insight 2: bearing responsibility is the heaviest part of the definition.

The definition states that the representative acts on behalf of the manufacturer and bears responsibility, with the two actions joined by a conjunction that treats them as one. In legislative drafting terms this means that representation rights and liability are inseparable; there is no choice between them. An authorized representative cannot enjoy the rights of representation while claiming not to bear the associated responsibility. This also determines that the criterion for selecting an authorized representative is not the quotation but the capacity to shoulder liability.

Insight 3: the obligations of the authorized representative span the entire life cycle.

Pulling together the obligations scattered across individual provisions reveals one continuous chain:

• Registration stage: submitting the application, signing the declaration of responsibility (Annex 10), receiving official documents;
• Import stage: handling imports for registration and expert review purposes (Article 30);
• Change stage: reporting changes to device data and information (Article 14);
• Post-market stage: fulfilling surveillance and vigilance obligations;
• Inspection stage: cooperating with inspections of production and circulation (Cabinet Resolution No. 450).

Five stages, one entity. This is why, in Part 05 of this series, we recommend hard-wiring exit and migration clauses into the agreement.

Insight 4: replacing the authorized representative affects far more than a single contract.

Replacing the authorized representative simultaneously touches the registration dossier records, the electronic system account, the import channel, and the entity responsible for post-market obligations. As we have noted, changes to the registration dossier must be completed under national rules by December 31, 2028, after which everything must be redone under Union rules. This means that the cost of replacing an authorized representative after 2029 will rise significantly, and securing a stable partner during the transition period carries real time value.

Insight 5: an individual entrepreneur may also serve, but the risk concentration is higher.

The definition allows a natural person registered as an individual entrepreneur to take on the role. This is legally feasible, but the continuity of operations and the capacity to bear liability of an individual entity are weaker than those of a legal entity. For products with long life cycles and large market shares, we recommend choosing a legal entity.

4. Practical recommendations

First, shift the selection criterion from price to capacity for responsibility. We recommend examining four items: whether dedicated regulatory staff are in place; whether there is experience with comparable products; whether there is genuine capability to handle imports, surveillance, and inspection cooperation; and whether there is a stable operating record and financial standing.

Second, the agreement must contain two major blocks: liability clauses and exit clauses. Liability clauses cover the obligations of the five stages; exit clauses cover return of materials, handover of accounts, cooperation on registration certificate amendments, transition arrangements, and allocation of costs.

Third, pre-set a replacement process for the authorized representative. We recommend agreeing in the contract on the notice period, cooperation obligations, handover checklist, processing deadlines, and cost allocation. Quantify in advance the cost of a change that may one day be needed.

Fourth, secure a long-term partner during the transition period. Given the rise in change costs after 2029, we recommend completing the long-term arrangement for the authorized representative before the end of 2027, avoiding a forced replacement in the late transition period.

5. Verification checklist

• □ The authorized representative meets all four statutory requirements: legal entity or individual entrepreneur, resident of the Kyrgyz Republic, holding a power of attorney from the manufacturer, bearing responsibility;
• □ Four items of liability capacity have been examined: dedicated regulatory staff, experience with comparable products, capability for import, surveillance, and inspection cooperation, and operating and financial stability;
• □ The agreement contains liability clauses covering the five stages: registration, import, changes, post-market, and inspections;
• □ The agreement contains exit and migration clauses: return of materials, account handover, cooperation on certificate amendments, transition arrangements, and cost allocation;
• □ A replacement process is pre-set: notice period, cooperation obligations, handover checklist, processing deadlines, and cost allocation;
• □ The long-term partner arrangement is completed before the end of 2027.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance coaching, post-market surveillance and vigilance system setup, import and distribution compliance, state fee estimation, and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations. It maintains a stable local cooperation network in Bishkek, Almaty, Tashkent, Moscow, and other cities, and works in Chinese, Russian, and English. For the key issues that foreign manufacturers commonly face in CIS markets, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection response, GRZAN provides executable solutions.

We hold to one principle: every regulatory conclusion we publish must be traceable to verifiable official sources. Any figure or timeline that cannot be verified is always labeled as a practical estimate, and experience values are never presented as legal grounds.

GRZAN provides registration and compliance support in Kyrgyzstan for medical device manufacturers, importers, and authorized representatives. For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services